Edition:
United States

China Biologic Products Holdings Inc (CBPO.OQ)

CBPO.OQ on NASDAQ Stock Exchange Global Select Market

98.19USD
4:00pm EDT
Change (% chg)

$0.06 (+0.06%)
Prev Close
$98.13
Open
$98.13
Day's High
$98.37
Day's Low
$97.57
Volume
74,453
Avg. Vol
74,321
52-wk High
$107.32
52-wk Low
$60.09

Latest Key Developments (Source: Significant Developments)

China Biologic Reports Financial Results For The Fourth Quarter And Fiscal Year 2018
Wednesday, 6 Mar 2019 05:00pm EST 

March 6 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2018.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.76.Q4 EARNINGS PER SHARE $0.87.BOARD OF DIRECTORS EXTENDS PREVIOUSLY APPROVED SHARE REPURCHASE PROGRAM.QTRLY TOTAL SALES $114.9 MILLION VERSUS $90.1 MILLION.CHINA BIOLOGIC PRODUCTS HOLDINGS - BOARD APPROVED EXTENSION TO PREVIOUSLY AUTHORIZED $100 MILLION SHARE REPURCHASE PROGRAM FOR ANOTHER 6 MONTHS UNTIL OCT 31, 2019.CHINA BIOLOGIC PRODUCTS HOLDINGS SEES 2019 NON-GAAP ADJUSTED INCOME FROM OPERATING AND NON-GAAP ADJUSTED NET INCOME TO INCREASE BY 4%-6% IN RMB TERMS OVER FY 2018 RESULTS.CHINA BIOLOGIC PRODUCTS HOLDINGS - TOTAL SALES, NON-GAAP ADJUSTED NET INCOME IN USD TERMS IN 2019 COULD BE AFFECTED BY FOREIGN CURRENCY TRANSLATION IMPACT.FY2019 EARNINGS PER SHARE VIEW $4.38, REVENUE VIEW $479.9 MILLION -- REFINITIV IBES DATA."ANTICIPATE THAT POLICY HEADWINDS WILL CONTINUE TO BE CHALLENGING IN SHORT TERM".  Full Article

China Biologic Products Holdings says On Feb 3, Board Elected Joseph Chow To Be New Chairman Of Board
Monday, 4 Feb 2019 10:37am EST 

Feb 4 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC PRODUCTS HOLDINGS- ON FEB 1, 2019, ZHIJUN TONG INFORMED CO THAT HE WAS RESIGNING FROM HIS POSITIONS AS PRESIDENT AND DIRECTOR OF CO.CHINA BIOLOGIC PRODUCTS HOLDINGS- ON FEB 1, 2019, ZHIJUN TONG INFORMED CO THAT HE WAS RESIGNING FROM HIS POSITIONS AS PRESIDENT AND DIRECTOR OF CO .CHINA BIOLOGIC PRODUCTS HOLDINGS- ON FEB 3, BOARD UNANIMOUSLY ELECTED JOSEPH CHOW TO BE NEW CHAIRMAN OF BOARD IN SUCCESSION TO DAVID HUI LI.CHINA BIOLOGIC PRODUCTS HOLDINGS- DAVID HUI LI CONTINUES TO SERVE AS A DIRECTOR ON THE BOARD - SEC FILING.  Full Article

China Biologic Reiterates Full Year 2018 Financial Forecast
Monday, 7 Jan 2019 08:00am EST 

Jan 7 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC REITERATES FULL YEAR 2018 FINANCIAL FORECAST.  Full Article

China Biologic Announces Dismissal Of Lawsuit Filed In Cayman Islands By Former Chairman
Friday, 14 Dec 2018 08:00am EST 

Dec 14 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC ANNOUNCES DISMISSAL OF LAWSUIT FILED IN CAYMAN ISLANDS BY FORMER CHAIRMAN.CHINA BIOLOGIC PRODUCTS - GRAND COURT OF CAYMAN ISLANDS DISMISSED LAWSUIT PREVIOUSLY FILED AGAINST CO BY FORMER CHAIRMAN, CEO DAVID (XIAOYING) GAO.  Full Article

David Gao Confirms Lawsuit Against China Biologic Products
Wednesday, 29 Aug 2018 11:59am EDT 

Aug 29 (Reuters) - David Gao :DAVID GAO CONFIRMS LAWSUIT AGAINST CHINA BIOLOGIC PRODUCTS TO PROTECT SHAREHOLDERS’ BEST INTERESTS.DAVID GAO - CONFIRMED FILED LAWSUIT AGAINST CO RELATED TO PRIVATE PLACEMENT OF SHARES TO SELECT INVESTOR GROUP.  Full Article

China Biologic Responds To Lawsuit Filed In Cayman Islands By Former Chairman
Tuesday, 28 Aug 2018 05:00pm EDT 

Aug 28 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC RESPONDS TO LAWSUIT FILED IN CAYMAN ISLANDS BY FORMER CHAIRMAN.CHINA BIOLOGIC PRODUCTS HOLDINGS - ISSUED STATEMENT IN RESPONSE TO LAWSUIT FILED AGAINST COMPANY IN CAYMAN ISLANDS BY DAVID (XIAOYING) GAO.CHINA BIOLOGIC PRODUCTS HOLDINGS INC - CLOSED 3.8 MILLION SHARES IN PRIVATE PLACEMENT & WILL CLOSE REMAINING IN ACCORDANCE WITH TRANSACTION AGREEMENTS.  Full Article

Investor Group Issues Statement Following China Biologic’s Private Placement Of Shares
Friday, 24 Aug 2018 12:35pm EDT 

Aug 24 (Reuters) - Investor Group::LEADING INVESTOR GROUP ISSUES STATEMENT FOLLOWING CHINA BIOLOGIC’S DILUTIVE PRIVATE PLACEMENT OF SHARES.INVESTOR GROUP SAYS IN RELATION TO CHINA BIOLOGIC'S REJECTION OF ITS PROPOSAL, "WILL EVALUATE ALL OPTIONS, INCLUDING LEGAL ACTION".  Full Article

PW Medtech Group To Purchase 800,000 China Biologic Products Shares For $80.72 Mln
Friday, 24 Aug 2018 10:40am EDT 

Aug 24 (Reuters) - PW Medtech Group Ltd <1358.HK>::CO TO PURCHASE 800,000 CHINA BIOLOGIC PRODUCTS (CBPO) SHARES, AT A PRICE OF US$100.9 PER CBPO SHARE.AGGREGATE PURCHASE PRICE FOR CBPO SHARES SHALL BE $80.72 MILLION.  Full Article

China Biologic Announces Receipt Of Competing Non-Binding Acquisition Proposal
Tuesday, 21 Aug 2018 08:00am EDT 

Aug 21 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC ANNOUNCES RECEIPT OF COMPETING NON-BINDING ACQUISITION PROPOSAL.CHINA BIOLOGIC PRODUCTS HOLDINGS INC - BOARD IS REVIEWING AND EVALUATING CONSORTIUM PROPOSAL AND CITIC PROPOSAL AND NO DECISIONS HAVE BEEN MADE.  Full Article

China Biologic Products Q2 Earnings Per Share $0.83
Friday, 3 Aug 2018 04:30pm EDT 

Aug 3 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018.Q2 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.17.Q2 EARNINGS PER SHARE $0.83.Q2 SALES ROSE 34.8 PERCENT TO $120.4 MILLION.SAYS REVISES FULL YEAR FINANCIAL FORECAST.IS MAKING A DOWNWARD REVISION TO ITS FULL YEAR 2018 FORECAST.EXPECTS FY2018 NON-GAAP ADJUSTED INCOME FROM OPERATIONS TO INCREASE BY 0% TO 2% IN RMB TERMS.CHINA BIOLOGIC PRODUCTS-"Q2 CONTINUED TO BE CHALLENGING DUE TO ONGOING IMPACT OF REGULATORY CHANGES & INTENSIFIED COMPETITION IN CHINA'S HEALTHCARE MARKET".SEES FY2018 NON-GAAP ADJUSTED NET INCOME TO DECREASE BY 2% TO 4% IN RMB TERMS.CHINA BIOLOGIC-2018 FORECAST WAS LOWERED TO ACCOUNT FOR WORSE-THAN-EXPECTED RESULTS FOR H1 2018 AND ONGOING CHALLENGING OUTLOOK IN H2 OF YEAR.CHINA BIOLOGIC PRODUCTS HOLDINGS-FOR H2, EXPECT "REGULATORY HEADWINDS AND MARKET COMPETITIVE DYNAMICS TO PERSIST", WHICH WILL IMPACT GUIDANCE FOR YEAR.  Full Article